{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T12:43:39Z","timestamp":1791895419173,"version":"4.3.4"},"reference-count":14,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,11,28]],"date-time":"2022-11-28T00:00:00Z","timestamp":1669593600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["esmoopen.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["ESMO Open"],"published-print":{"date-parts":[[2023,2]]},"DOI":"10.1016\/j.esmoop.2022.100750","type":"journal-article","created":{"date-parts":[[2023,1,10]],"date-time":"2023-01-10T17:03:23Z","timestamp":1673370203000},"page":"100750","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":66,"title":["How I treat diffuse large B-cell lymphoma"],"prefix":"10.1016","volume":"8","author":[{"given":"T.","family":"Melchardt","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Egle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Greil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/j.esmoop.2022.100750_bib1","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1056\/NEJMra2027612","article-title":"Diffuse large B-cell lymphoma","volume":"384","author":"Sehn","year":"2021","journal-title":"N\u00a0Engl J Med"},{"issue":"26","key":"10.1016\/j.esmoop.2022.100750_bib2","doi-asserted-by":"crossref","first-page":"3150","DOI":"10.1200\/JCO.2015.65.6520","article-title":"CNS international prognostic index: a risk model for CNS relapse in patients with diffuse large B-cell lymphoma treated with R-CHOP","volume":"34","author":"Schmitz","year":"2016","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.esmoop.2022.100750_bib3","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2022.103756","article-title":"The role of central nervous system (CNS) prophylaxis in preventing DLBCL patients from CNS relapse: a network meta-analysis","volume":"176","author":"Lin","year":"2022","journal-title":"Crit Rev Oncol Hematol"},{"issue":"8","key":"10.1016\/j.esmoop.2022.100750_bib4","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1093\/annonc\/mdy167","article-title":"ESMO Consensus Conference on malignant lymphoma: management of \u2018ultra-high-risk\u2019 patients","volume":"29","author":"Hutchings","year":"2018","journal-title":"Ann Oncol"},{"issue":"7","key":"10.1016\/j.esmoop.2022.100750_bib5","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1038\/s41375-022-01620-2","article-title":"The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: lymphoid neoplasms","volume":"36","author":"Alaggio","year":"2022","journal-title":"Leukemia"},{"issue":"10216","key":"10.1016\/j.esmoop.2022.100750_bib6","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1016\/S0140-6736(19)33008-9","article-title":"Four versus six cycles of CHOP chemotherapy in combination with six applications of rituximab in patients with aggressive B-cell lymphoma with favourable prognosis (FLYER): a randomised, phase 3, non-inferiority trial","volume":"394","author":"Poeschel","year":"2019","journal-title":"Lancet"},{"issue":"26","key":"10.1016\/j.esmoop.2022.100750_bib7","doi-asserted-by":"crossref","first-page":"3003","DOI":"10.1200\/JCO.20.00999","article-title":"Positron emission tomography-directed therapy for patients with limited-stage diffuse large B-cell lymphoma: results of Intergroup National Clinical Trials Network Study S1001","volume":"38","author":"Persky","year":"2020","journal-title":"J\u00a0Clin Oncol"},{"issue":"S2","key":"10.1016\/j.esmoop.2022.100750_bib8","doi-asserted-by":"crossref","DOI":"10.1002\/hon.5_2879","article-title":"Early positron emission tomography response-adapted treatment in localized diffuse large B-cell lymphoma (aaIPI=0): results of the phase 3 LYSA LNH 09-1B trial","volume":"39","author":"Bologna","year":"2021","journal-title":"Hematol Oncol"},{"issue":"4","key":"10.1016\/j.esmoop.2022.100750_bib9","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1056\/NEJMoa2115304","article-title":"Polatuzumab vedotin in previously untreated diffuse large B-cell lymphoma","volume":"386","author":"Tilly","year":"2022","journal-title":"N\u00a0Engl J Med"},{"issue":"7","key":"10.1016\/j.esmoop.2022.100750_bib10","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0133569","article-title":"Efficacy and cardiotoxicity of liposomal doxorubicin-based chemotherapy in advanced breast cancer: a meta-analysis of ten randomized controlled trials","volume":"10","author":"Xing","year":"2015","journal-title":"PLoS One"},{"issue":"4","key":"10.1016\/j.esmoop.2022.100750_bib11","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1111\/bjh.13463","article-title":"Front-line, dose-escalated immunochemotherapy is associated with a significant progression-free survival advantage in patients with double-hit lymphomas: a systematic review and meta-analysis","volume":"170","author":"Howlett","year":"2015","journal-title":"Br J Haematol"},{"issue":"12","key":"10.1016\/j.esmoop.2022.100750_bib12","doi-asserted-by":"crossref","first-page":"e609","DOI":"10.1016\/S2352-3026(18)30177-7","article-title":"Dose-adjusted EPOCH-R (etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab) in untreated aggressive diffuse large B-cell lymphoma with MYC rearrangement: a prospective, multicentre, single-arm phase 2 study","volume":"5","author":"Dunleavy","year":"2018","journal-title":"Lancet Haematol"},{"issue":"suppl 1","key":"10.1016\/j.esmoop.2022.100750_bib13","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1182\/blood-2019-127508","article-title":"Pivotal safety and efficacy results from Transcend NHL 001, a multicenter phase 1 study of lisocabtagene maraleucel (liso-cel) in relapsed\/refractory (R\/R) large B cell lymphomas","volume":"134","author":"Abramson","year":"2019","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.esmoop.2022.100750_bib14","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1056\/NEJMoa2116133","article-title":"Axicabtagene ciloleucel as second-line therapy for large B-cell lymphoma","volume":"386","author":"Locke","year":"2022","journal-title":"N\u00a0Engl J Med"}],"container-title":["ESMO Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702922003842?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702922003842?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T20:29:19Z","timestamp":1761856159000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2059702922003842"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2]]},"references-count":14,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,2]]}},"alternative-id":["S2059702922003842"],"URL":"https:\/\/doi.org\/10.1016\/j.esmoop.2022.100750","relation":{},"ISSN":["2059-7029"],"issn-type":[{"value":"2059-7029","type":"print"}],"subject":[],"published":{"date-parts":[[2023,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"How I treat diffuse large B-cell lymphoma","name":"articletitle","label":"Article Title"},{"value":"ESMO Open","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.esmoop.2022.100750","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}],"article-number":"100750"}}